MCID: ALP009
MIFTS: 60

Alopecia Areata

Categories: Rare diseases, Skin diseases, Genetic diseases, Immune diseases

Aliases & Classifications for Alopecia Areata

MalaCards integrated aliases for Alopecia Areata:

Name: Alopecia Areata 12 50 24 29 52 42 14 69
Cazenave's Vitiligo 50 69
Jonston's Alopecia 50 69
Marginal Alopecia 50 69
Celsus' Vitiligo 50 69
Diffuse Alopecia 50 69
Alopecia Totalis 24 69
Alopecia Celsi 50 69
Circumscribed Alopecia 12
Alopecia Circumscripta 50
Alopecia Cicatrisata 50
Patchy Alopecia 50
Pseudopelade 69
Alopecia 69
Aa 50

Classifications:



External Ids:

Disease Ontology 12 DOID:986
ICD10 33 L63 L63.9
ICD9CM 35 704.01
MeSH 42 D000506
UMLS 69 C0002171

Summaries for Alopecia Areata

NIH Rare Diseases : 50 alopecia areata (aa) is an autoimmune disease in which the immune system mistakenly attacks the hair follicles. in most cases, hair falls out in small, round patches on the scalp. although uncommon, hair loss can be more extensive in some people and affect other parts of the body. this condition can progress to complete loss of scalp hair (alopecia totalis) or total loss of all body hair (alopecia universalis). although the exact cause of aa is unknown, roughly 20% of affected people have a family member with alopecia, suggesting that genetic factors may contribute to the development of the condition. there is no cure or approved therapy for aa; however, some people find that medications approved for other purposes can help regrow hair. last updated: 11/23/2014

MalaCards based summary : Alopecia Areata, also known as cazenave's vitiligo, is related to autoimmune polyglandular syndrome type 3 and hepatitis b, and has symptoms including exanthema and pruritus. An important gene associated with Alopecia Areata is AIRE (Autoimmune Regulator), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs Acitretin and Methylprednisolone have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and skin, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and hematopoietic system

Disease Ontology : 12 A hypersensitivity reaction type II disease resulting in the loss of hair on the scalp and elsewhere on the body initially causing bald spots.

Wikipedia : 72 Alopecia areata, also known as spot baldness, is a condition in which hair is lost from some or all... more...

Related Diseases for Alopecia Areata

Diseases in the Alopecia Areata family:

Alopecia Areata 2 Alopecia Areata 1

Diseases related to Alopecia Areata via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 297)
id Related Disease Score Top Affiliating Genes
1 autoimmune polyglandular syndrome type 3 29.9 IFNG IL2 TNF
2 hepatitis b 29.5 GZMB IFNG IL2RA TNF
3 lymphoma 29.4 AIRE CTLA4 IFNG IL2 TNF
4 rheumatoid arthritis 28.0 CTLA4 ICAM1 IFNG IL1A IL1RN IL2
5 systemic lupus erythematosus 26.8 CTLA4 FASLG ICAM1 IFNG IL2 IL2RA
6 diffuse alopecia areata 12.3
7 alopecia areata 1 12.2
8 amyloidosis aa 12.2
9 helsmoortel-van der aa syndrome 12.2
10 alopecia universalis 12.1
11 alopecia areata 2 12.0
12 alopecia totalis 11.6
13 adnp syndrome 11.4
14 alopecia 11.2
15 aplastic anemia 11.1
16 cutaneous telangiectasia and cancer syndrome, familial 11.0
17 renal nutcracker syndrome 11.0
18 immunodeficiency 7, tcr-alpha/beta deficient 11.0
19 mental retardation, x-linked, syndromic, claes-jensen type 11.0
20 nail disorder, nonsyndromic congenital, 1 11.0
21 bier spots 11.0
22 sveinsson chorioretinal atrophy 10.9
23 aarskog-scott syndrome 10.9
24 superior mesenteric artery syndrome 10.9
25 7q11.23 duplication syndrome 10.9
26 chondrodysplasia punctata, x-linked dominant 10.9
27 ichthyosis follicularis atrichia photophobia syndrome 10.9
28 eye accommodation disease 10.8 IFNG IL2RA
29 squamous cell carcinoma, head and neck 10.7
30 amyloidosis, hereditary, transthyretin-related 10.7
31 williams-beuren region duplication syndrome 10.7
32 adnp-related intellectual disability and autism spectrum disorder 10.7
33 alport syndrome-intellectual disability-midface hypoplasia-elliptocytosis syndrome 10.7 IL2RA PTPN22
34 dermatitis herpetiformis, familial 10.7 IFNG IL1RN PTPN22
35 anterior segment dysgenesis 1, multiple subtypes 10.6 AIRE CTLA4
36 sternal cleft 10.6 IFNG TNF
37 clopidogrel resistance 10.6 AIRE CTLA4 PTPN22
38 askin's tumor 10.6 IFNG IL1A IL1RN
39 hernia of ovary and fallopian tube 10.6 HLA-A IL1RN
40 chronic lymphocytic inflammation with pontine perivascular enhancement responsive to steroids 10.5 IFNG IL1A IL2RA
41 bulbospinal polio 10.5 IFNG IL2
42 von economo's disease 10.5 GZMB IFNG
43 mosaic trisomy 1 10.5 IFNG TNF
44 senile reticular retinal degeneration 10.5 IFNG IL1RN TNF
45 primary systemic mycosis 10.5 IFNG TNF
46 anterior corneal pigmentation 10.5 HLA-A IL2RA PTPN22
47 autoinflammation with arthritis and dyskeratosis 10.5 AIRE CTLA4 PTPN22
48 vulvar nodular hidradenoma 10.5 AIRE IFNG IL2RA
49 placenta accreta 10.5 IL1A IL1RN IL2RA
50 bladder calculus 10.5 IL1RN TNF

Graphical network of the top 20 diseases related to Alopecia Areata:



Diseases related to Alopecia Areata

Symptoms & Phenotypes for Alopecia Areata

UMLS symptoms related to Alopecia Areata:


exanthema, pruritus

GenomeRNAi Phenotypes related to Alopecia Areata according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.72 IL2RA TNF GZMB ICAM1 IL1A IL2
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.72 TNF FASLG GZMB ICAM1 IL1A IL2

MGI Mouse Phenotypes related to Alopecia Areata:

44 (show all 11)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.25 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
2 cardiovascular system MP:0005385 10.24 CTLA4 CXCL10 FASLG ICAM1 IFNG IL1A
3 homeostasis/metabolism MP:0005376 10.22 ICAM1 IFNG IL1A IL1RN IL2 IL2RA
4 immune system MP:0005387 10.18 IL2RA MC2R PTPN22 TNF AIRE CTLA4
5 endocrine/exocrine gland MP:0005379 10.16 AIRE CTLA4 FASLG ICAM1 IFNG IL2
6 digestive/alimentary MP:0005381 10.13 AIRE CTLA4 FASLG ICAM1 IFNG IL2
7 mortality/aging MP:0010768 10.03 AIRE CTLA4 CXCL10 FASLG ICAM1 IFNG
8 liver/biliary system MP:0005370 9.87 PTPN22 TNF AIRE CTLA4 FASLG IFNG
9 neoplasm MP:0002006 9.7 AIRE FASLG ICAM1 IFNG IL1A IL2
10 respiratory system MP:0005388 9.56 IL2 IL2RA PTPN22 TNF AIRE CTLA4
11 vision/eye MP:0005391 9.17 AIRE FASLG ICAM1 IFNG IL2 IL2RA

Drugs & Therapeutics for Alopecia Areata

Drugs for Alopecia Areata (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 365)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Acitretin Approved Phase 4 55079-83-9 6437841 5284513
2
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
3
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
4
Triamcinolone Approved, Vet_approved Phase 4,Phase 2 124-94-7 31307
5
Finasteride Approved Phase 4,Phase 3,Phase 1,Phase 2 98319-26-7 57363
6
Minoxidil Approved Phase 4,Phase 3,Phase 1,Phase 2 38304-91-5 4201
7
Imiquimod Approved, Investigational Phase 4,Phase 3 99011-02-6 57469
8
Hydroxychloroquine Approved Phase 4 118-42-3 3652
9
Betamethasone Approved, Vet_approved Phase 4 378-44-9 9782
10
Latanoprost Approved, Investigational Phase 4 130209-82-4 5282380 5311221
11
Capsaicin Approved Phase 4 404-86-4 1548943
12
Bimatoprost Approved, Investigational Phase 4,Phase 2,Phase 1 155206-00-1 5311027
13
Doxorubicin Approved, Investigational Phase 4,Phase 2,Phase 3 23214-92-8 31703
14
Drospirenone Approved Phase 4 67392-87-4 68873
15
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
16
Ethinyl Estradiol Approved Phase 4 57-63-6 5991
17
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 5460373 44475014
18
Spironolactone Approved Phase 4,Phase 2 1952-01-7, 52-01-7 5833
19 Orange Approved, Nutraceutical Phase 4
20
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 59-30-3 6037
21
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
22
leucovorin Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Phase 1 58-05-9 143 6006
23
Manganese Approved, Nutraceutical Phase 4 7439-96-5 27854
24
Clobetasol Investigational Phase 4,Phase 3 25122-46-7, 25122-41-2 32798 5311051
25
Doxil Approved June 1999 Phase 4,Phase 2,Phase 3 31703
26 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1
27 Dermatologic Agents Phase 4,Phase 3,Phase 1,Phase 2
28 Emollients Phase 4
29 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1
30 Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
31 Hormones Phase 4,Phase 3,Phase 1,Phase 2
32 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 1,Phase 2
33 Keratolytic Agents Phase 4
34 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2,Phase 1
35 Anti-Infective Agents Phase 4,Phase 3,Phase 2,Phase 1
36 Anti-Asthmatic Agents Phase 4,Phase 1,Phase 2
37 Antihypertensive Agents Phase 4,Phase 3,Phase 1,Phase 2
38 Respiratory System Agents Phase 4,Phase 1,Phase 2
39 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
40 Antiemetics Phase 4,Phase 2,Phase 1
41 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
42 Autonomic Agents Phase 4,Phase 1,Phase 2
43 Gastrointestinal Agents Phase 4,Phase 2,Phase 1
44 Methylprednisolone acetate Phase 4
45 Methylprednisolone Hemisuccinate Phase 4
46 Neuroprotective Agents Phase 4,Phase 2
47 Prednisolone acetate Phase 4
48 Prednisolone hemisuccinate Phase 4
49 Prednisolone phosphate Phase 4
50 Protective Agents Phase 4,Phase 2,Phase 3,Phase 1

Interventional clinical trials:

(show top 50) (show all 321)

id Name Status NCT ID Phase Drugs
1 Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia Unknown status NCT01111981 Phase 4 Clobetasol Propionate 0.05% Emollient Foam
2 Low-Dose (17.5 mg/Day) Acitretin: Comparable Efficacy Without the Side Effects? Unknown status NCT01228409 Phase 4 Acitretin 17.5 mg/day
3 Arrhythmia Restart Prevention and RatE STabilization in Atrial Fibrillation Unknown status NCT00224341 Phase 4
4 Aldara for the Treatment of Extensive Alopecia Areata Completed NCT00177021 Phase 4 Aldara Cream 5%
5 Characteristics of T Cells From Alopecia Areata Scalp Skin Before and After Treatment With Aldara 5% Completed NCT00176943 Phase 4 Aldara Cream 5%
6 Plaquenil for Alopecia Areata, Alopecia Totalis Completed NCT00176982 Phase 4 Hydroxychloroquine
7 Comparison of Topical Latanoprost vs Topical Corticosteroid in Treatment of Localized Alopecia Areata Completed NCT02350023 Phase 4 Topical latanoprost 0.005%;Topical betamethasone 0.05%
8 Response of Topical Capsaicin in Alopecia Areata Completed NCT00176969 Phase 4 Capsaicin
9 Safety and Efficacy of Oral Mega Pulse Methylprednisolone in Severe Therapy Resistant Alopecia Areata Completed NCT01167946 Phase 4 methylprednisolone sodium succinate;methylprednisolone sodium succinate;methylprednisolone sodium succinate
10 Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children Completed NCT01023841 Phase 4 bimatoprost ophthalmic solution 0.03%;Vehicle Sterile Solution
11 Doxorubicin Pharmacokinetics and Response in Non Hodgkin's Lymphoma Completed NCT00969462 Phase 4 Doxorubicin
12 Topical Imiquimod Cream in Combination With Cryotherapy for the Treatment of Actinic Keratoses Completed NCT00774787 Phase 4 imiquimod 5% cream
13 Clinical, Metabolic and Endocrine Effects of the Treatment With Drospirenone and Ethinyl Estradiol Alone or in Combination With Myo-inositol in Young Women With Polycystic Ovary Syndrome (PCOS) and Insulin Resistance Completed NCT01511822 Phase 4 Drospirenone Ethinyl estradiol;Drospirenone Ethinyl estradiol Myo-inositol;placebo
14 Myo-inositol Versus D-chiro-inositol in the Treatment of Polycystic Ovary Syndrome and Insulin Resistance: Evaluation of Clinical, Metabolic, Endocrine and Ultrasound Parameters Completed NCT01514942 Phase 4 Folic acid, vit B12;Folic acid, vit B12
15 A Phase 4, Placebo-Controlled, Randomized Study to Evaluate the Immunogenicity and Safety of HPV and Tdap When Administered With MenACWY in Adolescents Completed NCT01424644 Phase 4
16 Intralesional Steroids in the Treatment of Alopecia Areata Recruiting NCT01898806 Phase 4 Intralesional Triamcinolone 2.5 mg/ml;Intralesional Triamcinolone 5 mg/ml;Intralesional Triamcinolone 10 mg/ml;Intralesional Saline
17 Comparing Different Platelet Rich Plasma (PRP) Treatment Regimens for Management of Androgenic Alopecia Active, not recruiting NCT02999737 Phase 4
18 The Use of 5mg Finasteride Versus 200mg Spironolactone and Topical 5% Minoxidil in Treating Postmenopausal Female Androgenetic Alopecia Withdrawn NCT02483195 Phase 4 5% Minoxidil;200mg Spironolactone;5mg Finasteride
19 Efficacy and Safety of Mesotherapy With Minoxidil 0.5%/2ml for Androgenetic Alopecia in Female Patients Unknown status NCT01655108 Phase 3 Minoxidil;Saline
20 Reflexology's Effect on Polycystic Ovary Syndrome: A Pilot Study Unknown status NCT00746148 Phase 3
21 Reflexology's Effect on Polycystic Ovary Syndrome (PCOS) Unknown status NCT00744510 Phase 3
22 Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous Unknown status NCT01222000 Phase 3 apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side;apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
23 Phase II Randomized Bilateral Comparison of Topical Targretin Gel 1% in Alopecia Areata Completed NCT00063076 Phase 2, Phase 3 Targretin Gel 1%
24 A Trial of Clobetasol Propionate Versus Hydrocortisone in Children With Alopecia Areata Completed NCT01453686 Phase 3 Hydrocortisone 1%;Clobetasol Propionate 0.05%
25 The Randomized Double-blind Placebo-controlled Trial of Intralesional Botulinum Toxin A Injection for Recalcitrant Alopecia Totalis and Alopecia Universalis Completed NCT00997815 Phase 2, Phase 3 Botulinum toxin A;Normal saline injection
26 A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss Completed NCT00151515 Phase 3 minoxidil
27 Clinical Trial in Females With Female Pattern Hair Loss Completed NCT01145625 Phase 3 5% Minoxidil;2% Minoxidil
28 Clinical Trial in Females for Female Pattern Hair Loss Completed NCT01226459 Phase 3 5% Minoxidil Topical Foam;Vehicle Topical Foam
29 Efficacy and Safety Study to Compare Two Minoxidil Formulations on Women With Androgenetic Alopecia Completed NCT00958750 Phase 3 minoxidil
30 A Study To Assess The Efficacy And Safety Of Dutasteride 0.5mg Once Daily For 6 Months In The Treatment Of Male Subjects With Androgenetic Alopecia Completed NCT00441116 Phase 3 Dutasteride 0.5mg oral tablets
31 A Long-term Study to Determine Safety and Efficacy of Dutasteride in Male Subjects With Androgenetic Alopecia Completed NCT01831791 Phase 3 Dutasteride 0.5 mg
32 Efficacy Study of Minoxidil Lotion Versus Combined Minoxidil and Finasteride Lotion to Treat Male Pattern Hair Loss Completed NCT01391156 Phase 3 3%Minoxidil lotion;3% Minoxidil with 0.1% Finasteride lotion
33 Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia Completed NCT02014584 Phase 3 Dutasteride;Placebo
34 Dutasteride Versus Placebo and Finasteride in Men With Androgenetic Alopecia Completed NCT01231607 Phase 3 1mg Finasteride active;0.02mg dutasteride;0.1mg dutasteride;0.5mg dutasteride;Finasteride placebo;Dutasteride placebo
35 Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM) Completed NCT01590238 Phase 3
36 Effects of Finasteride on Serum Prostate-Specific Antigen (0906-111) Completed NCT00396175 Phase 3 MK0906, finasteride / Duration of Treatment : 48 Weeks;Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks
37 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up Completed NCT02549352 Phase 3 LEO43204 gel;Vehicle gel
38 Efficacy and Safety of LEO 43204 in Field Treatment of Actinic Keratosis on Balding Scalp Including 12-month Follow-up Completed NCT02547363 Phase 3 LEO 43204 gel;Vehicle gel
39 A Randomized, Double-Blind, Parallel-Group, Vehicle-Controlled, Multicenter Study Comparing Diclofenac Sodium Gel, 3% to Solaraze® Gel, 3% in the Treatment of Actinic Keratosis on the Face or Bald Scalp Completed NCT02611804 Phase 3 Diclofenac sodium;Diclofenac sodium;Placebo
40 Study Comparing Imiquimod Cream, 3.75% to Zyclara® (Imiquimod) Cream, 3.75% in the Treatment of Actinic Keratosis Completed NCT01686152 Phase 3 Imiquimod Cream, 3.75%;Zyclara®
41 Efficacy and Safety of Ingenol Mebutate Gel for Actinic Keratosis Applied on Large Area on Face, Scalp or Chest Completed NCT02361216 Phase 3 Ingenol Mebutate
42 Safety and Effectiveness Study of Imiquimod Creams for the Treatment of Actinic Keratoses (AKs) Completed NCT00603798 Phase 3 Imiquimod cream;Placebo cream;Imiquimod cream
43 Safety and Effectiveness Study of Imiquimod Creams for Treatment of Actinic Keratoses (AKs) Completed NCT00605176 Phase 3 imiquimod cream;imiquimod cream;Placebo
44 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117767 Phase 3 Terbinafine hydrochloride (HCl);Griseofulvin
45 Terbinafine Compared to Griseofulvin in Children With Tinea Capitis Completed NCT00117754 Phase 3 Terbinafine hydrochloride
46 A Study to Evaluate the Safety and Efficacy Imiquimod Cream, 2.5% in Subjects With Actinic Keratoses Completed NCT02120898 Phase 3 Imiquimod
47 Multicenter, Double-blind, Placebo Controlled Comparing Test Fluorouracil Cream to Carac Cream in Actinic Keratosis Completed NCT02616601 Phase 3 Carac Cream;Generic Fluorouracil Cream;Placebo
48 Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer Completed NCT01426880 Phase 2, Phase 3 Carboplatin;background treatment
49 Effect of NovoTTF-100A Together With Temozolomide in Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00916409 Phase 3 Temozolomide
50 Assessment of the Transfer of Using Levonorgestrel Intrauterine System (LNG IUS) as a Contraceptive to Using it as Part of Hormone Replacement Therapy (HRT). Completed NCT00185458 Phase 3 LNG IUS

Search NIH Clinical Center for Alopecia Areata

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: alopecia areata

Genetic Tests for Alopecia Areata

Genetic tests related to Alopecia Areata:

id Genetic test Affiliating Genes
1 Alopecia Areata 29 24

Anatomical Context for Alopecia Areata

MalaCards organs/tissues related to Alopecia Areata:

39
Breast, Brain, Skin, Ovary, Testes, T Cells, Lung

Publications for Alopecia Areata

Articles related to Alopecia Areata:

(show top 50) (show all 774)
id Title Authors Year
1
Alopecia Areata: a Comprehensive Review of Pathogenesis and Management. ( 28717940 )
2017
2
Ausschreibung Forschungspreis Alopecia areata. ( 28872235 )
2017
3
Increased expression of PD-L1 and PD-L2 in dermal fibroblasts from alopecia areata mice. ( 28777458 )
2017
4
UVA-1 in the treatment of alopecia areata. ( 28834031 )
2017
5
Vitamin D Level in Alopecia Areata. ( 28794553 )
2017
6
Increased blood levels of NKG2D(+)CD4(+) TA cells in patients with alopecia areata. ( 27986136 )
2017
7
Alopecia areata as a paraneoplastic syndrome of gastric cancer. ( 27990839 )
2017
8
Alopecia areata complicated with Good's syndrome. ( 28925501 )
2017
9
Tofacitinib for the treatment of severe alopecia areata and variants: A study of 90 patients. ( 27816293 )
2017
10
Alopecia Areata on Vertex as a Potential Pitfall for Misdiagnosis of Central Centrifugal Cicatricial Alopecia in African-American Women. ( 28839392 )
2017
11
A Case Report of Verruca Vulgaris on basis of Alopecia Areata Successfully Treated with Diphenylcyclopropenone. ( 28761264 )
2017
12
Bilateral Half-Head Comparison of 1% Anthralin Ointment in Children with Alopecia Areata. ( 28044367 )
2017
13
Lupus erythematosus tumidus of the scalp masquerading as alopecia areata. ( 28319635 )
2017
14
Common phenotype and different non-HLA genes in Graves' disease and alopecia areata. ( 27810496 )
2017
15
Minoxidil-Induced Hypertrichosis in a Child with Alopecia Areata. ( 28405563 )
2017
16
Large Scale Epitope Identification Screen and Its Potential Application to the Study of Alopecia Areata. ( 28864075 )
2017
17
Trichotillomania: a case report with clinical and dermatoscopic differential diagnosis with alopecia areata. ( 28225970 )
2017
18
Unsuccessful Treatment of Alopecia Areata with Simvastatin/Ezetimibe: Experience in 12 Patients. ( 28879192 )
2017
19
Efficacy of combining pulse corticotherapy and methotrexate in alopecia areata: Real-life evaluation. ( 28940756 )
2017
20
Establishing and Prioritising Research Questions for the Prevention, Diagnosis and Treatment of Hair Loss (excluding Alopecia Areata): The Hair Loss Priority Setting Partnership. ( 28714061 )
2017
21
Long-term result of hair transplantation for therapy resistant alopecia areata of eyebrows. ( 28731020 )
2017
22
Tofacitinib for the treatment of alopecia areata and variants in adolescents. ( 27816292 )
2017
23
Home-based contact immunotherapy with diphenylcyclopropenone for alopecia areata is as effective and safe as clinic-based treatment in patients with stable disease: A retrospective study of 40 patients. ( 28947296 )
2017
24
Shedding Light on Alopecia Areata in Pediatrics: A Retrospective Analysis of Comorbidities in Children in the National Alopecia Areata Registry. ( 28884897 )
2017
25
Nilotinib-induced Keratosis Pilaris Associated with Alopecia Areata and Eyebrow Thinning. ( 28839396 )
2017
26
Trichoscopic clues for diagnosis of alopecia areata and trichotillomania in Asians. ( 28074524 )
2017
27
A Case of Alopecia Areata in a Patient with Turner Syndrome. ( 28785342 )
2017
28
Lack of efficacy of apremilast in 9 patients with severe alopecia areata. ( 28917463 )
2017
29
Evaluation of the Relationship between Alopecia Areata and Viral Antigen Exposure. ( 28801732 )
2017
30
Bullying and Quality of Life in Pediatric Alopecia Areata. ( 28879186 )
2017
31
Evaluation of Clinical Significance of Dermoscopy in Alopecia Areata. ( 27904180 )
2016
32
Two Episodes of Simultaneous Identical Alopecia Areata in Identical Twins. ( 27127382 )
2016
33
Immune-related alopecia (areata and universalis-type) in cancer patients receiving immune checkpoint inhibitors. ( 27943234 )
2016
34
Liquid Nitrogen Cryotherapy in Recalcitrant Alopecia Areata: A Study of 11 Patients. ( 27127370 )
2016
35
Revisiting Coudability Hairs in Alopecia Areata: The Story behind the Name. ( 27843931 )
2016
36
Linear Alopecia Areata. ( 27625568 )
2016
37
Alopecia areata and narcolepsy: a tale of obscure autoimmunity. ( 27060069 )
2016
38
Childhood epidermolysis bullosa acquisita during squaric acid dibutylester (SADBE) immunotherapy for alopecia areata. ( 27208509 )
2016
39
Concurrence of Immune Thrombocytopenic Purpura and Alopecia Areata: A Rare Association. ( 27127385 )
2016
40
Transient Efficacy of Tofacitinib in Alopecia Areata Universalis. ( 27194979 )
2016
41
A Comparison of Vertical and Transverse Sections in the Histological Diagnosis of Alopecia Areata Scalp Biopsy Specimens. ( 27625562 )
2016
42
Trichoscopy as a useful method to differentiate tinea capitis from alopecia areata in children at Zagazig University Hospitals. ( 27654953 )
2016
43
CURRENT AND FUTURE TREATMENTS OF ALOPECIA AREATA AND TRICHOTILLOMANIA IN CHILDREN. ( 27484130 )
2016
44
ULBP3: a marker for alopecia areata incognita. ( 27142445 )
2016
45
Alopecia areata, thyroiditis and vitiligo vulgaris in a Japanese patient with smoldering type adult T-cell leukemia/lymphoma. ( 27651025 )
2016
46
Distinguishing diffuse alopecia areata (AA) from pattern hair loss (PHL) using CD3(+) TA cells. ( 26851831 )
2016
47
CD8+ mycosis fungoides clinically masquerading as alopecia areata. ( 27546732 )
2016
48
Alopecia Areata in an Adolescent With Inflammatory Bowel Disease. ( 27886980 )
2016
49
Alopecia areata (AA) and treatment with simvastatin/ezetimibe: Experience of 20 patients. ( 27085249 )
2016
50
Estimated serum vitamin D status, vitamin D intake, and risk of incident alopecia areata among US women. ( 27664090 )
2016

Variations for Alopecia Areata

Expression for Alopecia Areata

Search GEO for disease gene expression data for Alopecia Areata.

Pathways for Alopecia Areata

Pathways related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 49)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 CTLA4 CXCL10 FASLG HLA-A ICAM1 IFNG
2
Show member pathways
13.32 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
3
Show member pathways
13.28 CXCL10 FASLG IL1A IL2 IL2RA PTPN22
4
Show member pathways
12.85 CXCL10 FASLG IFNG IL2 TNF
5
Show member pathways
12.7 CTLA4 FASLG GZMB HLA-A ICAM1 IFNG
6
Show member pathways
12.67 CXCL10 FASLG HLA-A ICAM1 IFNG IL1A
7 12.63 FASLG HLA-A IL2 IL2RA TNF
8
Show member pathways
12.59 IFNG IL1A IL2 IL2RA TNF
9
Show member pathways
12.5 FASLG GZMB HLA-A ICAM1 IFNG IL2
10
Show member pathways
12.43 CTLA4 IFNG IL1A IL2 TNF
11 12.42 HLA-A ICAM1 IL2 IL2RA TNF
12
Show member pathways
12.24 FASLG GZMB IL1A TNF
13
Show member pathways
12.18 CXCL10 FASLG IFNG TNF
14
Show member pathways
12.17 HLA-A IFNG IL1A IL2 TNF
15 12.09 ICAM1 IFNG IL1A TNF
16 12 IFNG IL2 IL2RA TNF
17 11.99 FASLG ICAM1 IL1A TNF
18 11.99 CXCL10 ICAM1 IFNG IL1A IL2 TNF
19
Show member pathways
11.97 IL1A IL2 IL2RA
20
Show member pathways
11.93 FASLG GZMB HLA-A IFNG IL2 IL2RA
21 11.91 CXCL10 ICAM1 TNF
22
Show member pathways
11.9 IFNG IL2 TNF
23 11.89 CTLA4 ICAM1 IFNG IL1A TNF
24 11.86 ICAM1 IL1A TNF
25 11.85 IL1A IL2RA TNF
26 11.83 GZMB IFNG IL2 IL2RA TNF
27 11.82 CTLA4 CXCL10 FASLG GZMB IFNG IL1RN
28 11.78 ICAM1 IFNG IL2
29 11.74 IFNG IL2 TNF
30 11.74 CTLA4 ICAM1 IL2RA TNF
31
Show member pathways
11.73 CTLA4 FASLG IFNG IL2 IL2RA TNF
32
Show member pathways
11.69 ICAM1 IFNG IL1A IL2 TNF
33
Show member pathways
11.68 FASLG IL2 IL2RA
34 11.59 FASLG IFNG IL2 TNF
35 11.54 ICAM1 IFNG TNF
36 11.54 CXCL10 ICAM1 IL1A IL1RN TNF
37 11.53 FASLG IFNG IL1A TNF
38 11.52 IFNG IL2 TNF
39 11.51 IFNG IL2 IL2RA
40 11.47 FASLG ICAM1 IFNG
41 11.4 FASLG ICAM1 IFNG TNF
42 11.39 CXCL10 ICAM1 IFNG
43 11.33 IFNG IL2 IL2RA
44 11.33 IFNG IL1A IL2 TNF
45
Show member pathways
11.29 FASLG GZMB HLA-A IFNG IL2 IL2RA
46 11.25 IFNG IL2 IL2RA
47 11.23 CXCL10 FASLG IL1A IL2 TNF
48
Show member pathways
11.23 FASLG GZMB IFNG IL2 IL2RA TNF
49 10.9 ICAM1 TNF

GO Terms for Alopecia Areata

Cellular components related to Alopecia Areata according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.56 CXCL10 FASLG ICAM1 IFNG IL1A IL1RN
2 cell surface GO:0009986 9.55 FASLG HLA-A ICAM1 IL2RA TNF
3 external side of plasma membrane GO:0009897 9.17 CTLA4 CXCL10 FASLG ICAM1 IFNG IL2RA

Biological processes related to Alopecia Areata according to GeneCards Suite gene sharing:

(show all 28)
id Name GO ID Score Top Affiliating Genes
1 immune system process GO:0002376 9.97 CTLA4 HLA-A IL2 IL2RA PTPN22
2 response to lipopolysaccharide GO:0032496 9.85 CXCL10 FASLG ICAM1 PTPN22
3 inflammatory response GO:0006954 9.85 CXCL10 IL1A IL1RN IL2RA TNF
4 response to virus GO:0009615 9.8 CXCL10 IFNG TNF
5 interferon-gamma-mediated signaling pathway GO:0060333 9.75 HLA-A ICAM1 IFNG
6 positive regulation of T cell proliferation GO:0042102 9.73 IFNG IL2 IL2RA
7 humoral immune response GO:0006959 9.71 AIRE IFNG TNF
8 positive regulation of T cell differentiation GO:0045582 9.64 IL2 IL2RA
9 response to copper ion GO:0046688 9.62 ICAM1 IL1A
10 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IFNG TNF
11 negative regulation of growth of symbiont in host GO:0044130 9.61 IFNG TNF
12 positive regulation of nitric oxide biosynthetic process GO:0045429 9.61 ICAM1 IFNG TNF
13 negative regulation of immune response GO:0050777 9.6 CTLA4 IL2RA
14 positive regulation of isotype switching to IgG isotypes GO:0048304 9.59 IFNG IL2
15 positive regulation of chemokine biosynthetic process GO:0045080 9.58 IFNG TNF
16 extrinsic apoptotic signaling pathway GO:0097191 9.58 FASLG IFNG TNF
17 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.52 ICAM1 TNF
18 negative regulation of lymphocyte proliferation GO:0050672 9.51 IL2 IL2RA
19 necroptotic signaling pathway GO:0097527 9.49 FASLG TNF
20 cellular response to lipopolysaccharide GO:0071222 9.46 CXCL10 ICAM1 IFNG TNF
21 regulation of T cell homeostatic proliferation GO:0046013 9.37 IL2 IL2RA
22 immune response GO:0006955 9.36 AIRE CTLA4 CXCL10 FASLG HLA-A IFNG
23 inflammatory cell apoptotic process GO:0006925 9.32 FASLG IFNG
24 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.26 IFNG TNF
25 fever generation GO:0001660 9.18 IL1A
26 positive regulation of vitamin D biosynthetic process GO:0060557 8.96 IFNG TNF
27 positive regulation of transcription from RNA polymerase II promoter GO:0045944 10.08 AIRE CXCL10 IFNG IL1A IL2 TNF
28 apoptotic process GO:0006915 10.03 FASLG GZMB IFNG IL1A IL2RA

Molecular functions related to Alopecia Areata according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.17 CXCL10 FASLG IFNG IL1A IL1RN IL2
2 interleukin-1 receptor binding GO:0005149 8.96 IL1A IL1RN

Sources for Alopecia Areata

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....